AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing With Starting Material

Global CDMO’s Heidelberg Facility Supplies more pDNA material to help address growing needs

Heidelberg, Germany, Feb 9 (Bernama-GLOBE NEWSWIRE) —AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced an expanded partnership to supply more plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.

http://mrem.bernama.com/viewsm.php?idm=42363

administrator

Related Articles